IDEX Corporation (IEX) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and IDEX published the results on October 28, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. IDEX reports EPS two ways: GAAP, under the accounting rules every US filer follows, and Adjusted diluted EPS, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Q3 2026 segment results include Micro-LAM, Inc., acquired in July 2025, in Health & Science Technologies.

Source: IDEX Q3 2026 results, October 28, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How IDEX splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• IDEX's Health & Science Technologies revenue was $434 million in Q3 2026, up 14% from $381 million in Q3 2025, 46% of total revenue.
• IDEX's Fluid & Metering Technologies revenue was $328 million in Q3 2026, up 3% from $317 million in Q3 2025, 34% of total revenue.
• IDEX's Fire & Safety/Diversified Products revenue was $192 million in Q3 2026, up 5% from $182 million in Q3 2025, 20% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

IDEX does not reconcile its forward-looking non-GAAP measures to GAAP and gives no reported-basis sales or EPS outlook.

In its Q3 2026 release, IDEX said:

“Full year organic sales projected to increase 6.5% to 6.8% over the prior year, up from previous guidance of 5% to 6%”

“Full year adjusted diluted EPS of $8.91 to $8.96, up approximately 12% year-over-year at midpoint, up from previous guidance of $8.70 to $8.85”

Source: IDEX Q3 2026 release, Oct 28, 2026.

This is the company's own guidance as of Oct 28, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the IEX forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP net sales and diluted EPS attributable to IDEX, each as first reported in that quarter's release.

We do not hold a confirmed date for IDEX's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 28, 2026

IDEX reports net sales in three segments. In Q3 2026 Health & Science Technologies brought in $433.5 million of the $951.7 million total, Fluid & Metering Technologies $327.9 million and Fire & Safety/Diversified Products $191.5 million, with $1.2 million of intersegment eliminations. Sales rose 8% on both a reported and an organic basis. (IDEX Q3 2026 release, Oct 28, 2026)

Health & Science Technologies grew 14%, or 13% organically. IDEX said the higher volumes came primarily from AI-driven demand for data center power and semiconductor markets, plus strength in space and defense and positive price. The segment makes precision fluidics, pumps, sealing components, optical components and coatings, technical ceramics and other engineered parts, and its Adjusted EBITDA margin rose 110 basis points to 28.8%. (IDEX Q3 2026 release, Oct 28, 2026; IDEX Form 10-K, 2025, Feb 19, 2026)

Fluid & Metering Technologies grew 3% (4% organic), mainly on price: higher volumes in municipal water, semiconductor and industrial markets were partly offset by lower volumes in chemical markets as well as in agriculture and energy. Fire & Safety/Diversified Products grew 5% (6% organic) on higher volumes in the BAND-IT and Fire & Safety businesses and positive price. (IDEX Q3 2026 release, Oct 28, 2026)

Half of IDEX's sales are outside the U.S. International sales were $478.2 million in the quarter, up 14%, against domestic sales of $473.5 million, up 3%. In Health & Science Technologies, international sales rose 27% to $249.3 million while domestic sales were flat at $184.2 million. (IDEX Form 10-Q, Q3 2026, Oct 28, 2026)

IDEX's Q3 2026 diluted EPS was $1.95 on a GAAP basis and $2.33 adjusted, both up 15%. The largest adjustment is acquisition-related intangible asset amortization, $0.42 per share before a $0.10 tax effect. Restructuring expenses, asset impairments and related charges added $0.06 before tax, mostly accelerated depreciation tied to the anticipated closure of a facility in Health & Science Technologies. (IDEX Q3 2026 release, Oct 28, 2026)

Diluted weighted average shares fell to 74.0 million from 75.2 million. IDEX repurchased 1.1 million shares at a cost of $227.0 million in the first nine months of 2026, and returned $129 million to shareholders through dividends and share repurchases in the quarter. (IDEX Q3 2026 release, Oct 28, 2026; IDEX Form 10-Q, Q3 2026, Oct 28, 2026)

The effective tax rate was 25.2%, against 25.1% a year earlier. The 10-Q says the Q3 2026 rate includes a discrete tax expense related to reserves on an ongoing state audit. (IDEX Form 10-Q, Q3 2026, Oct 28, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

IDEX gives full-year guidance for organic sales growth and adjusted diluted EPS in its release, and raised both with Q3 2026: organic sales growth of 6.5% to 6.8% (previously 5% to 6%) and adjusted diluted EPS of $8.91 to $8.96 (previously $8.70 to $8.85), up about 12% at the midpoint. It does not reconcile these to GAAP, citing items such as foreign exchange, acquisitions and restructuring that it cannot reasonably estimate. (IDEX Q3 2026 release, Oct 28, 2026)

A consensus figure is the average of the models published by the analysts who cover IDEX, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones IDEX's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning IEX is on is IEX a buy or a sell?, what analysts expect next is on the IEX forecast, and what the company does is on the IDEX Corporation (IEX) stock page.

Every number on this page can be traced to a document IDEX published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.